

Perspective

Large language models and synthetic health data: progress and prospects

Daniel Smolyak , MS¹, Margrét V. Bjarnadóttir, PhD², Kenyon Crowley, PhD³,
Ritu Agarwal, PhD^{*4}

¹Department of Computer Science, University of Maryland, College Park, College Park, MD 20742, United States, ²Robert H. Smith School of Business, University of Maryland, College Park, College Park, MD 20740, United States, ³Accenture Federal Services, Arlington, VA 22203, United States, ⁴Center for Digital Health and Artificial Intelligence, Carey Business School, Johns Hopkins University, Baltimore, MD 21202, United States

*Corresponding author: Ritu Agarwal, PhD, Center for Digital Health and Artificial Intelligence, Carey Business School, Johns Hopkins University, 100 International Drive, Baltimore, MD 21202, United States (ritu.agarwal@jhu.edu)

Abstract

Objectives: Given substantial obstacles surrounding health data acquisition, high-quality synthetic health data are needed to meet a growing demand for the application of advanced analytics for clinical discovery, prediction, and operational excellence. We highlight how recent advances in large language models (LLMs) present new opportunities for progress, as well as new risks, in synthetic health data generation (SHDG).

Materials and Methods: We synthesized systematic scoping reviews in the SHDG domain, recent LLM methods for SHDG, and papers investigating the capabilities and limits of LLMs.

Results: We summarize the current landscape of generative machine learning models (eg, Generative Adversarial Networks) for SHDG, describe remaining challenges and limitations, and identify how recent LLM approaches can potentially help mitigate them.

Discussion: Six research directions are outlined for further investigation of LLMs for SHDG: evaluation metrics, LLM adoption, data efficiency, generalization, health equity, and regulatory challenges.

Conclusion: LLMs have already demonstrated both high potential and risks in the health domain, and it is important to study their advantages and disadvantages for SHDG.

Lay Summary

There is growing interest in the application of machine learning models and advanced analytics to various healthcare processes and operations, including the generation of new clinical discoveries, development of high-quality predictions, and optimization of administrative processes. Machine learning models for prediction and classification rely on extensive and robust datasets, particularly for deep learning models common in health, creating an urgent need for large health datasets. Yet datasets can be insufficiently large due to the rapid evolution of diseases, such as coronavirus disease 2019 (COVID-19), rarity of disease, or the myriad obstacles to sharing and acquiring existing health data, including ethical, legal, political, economic, cultural, and technical barriers. Synthetic data provide a unique opportunity for health dataset expansion or creation by addressing privacy concerns and other barriers. In this paper, we review prior literature and discuss the landscape of machine learning models used for synthetic health data generation (SHDG), outlining challenges and limitations. We build on existing research on the state of the art in SHDG and prior broad explorations of the potential risks and opportunities for large language models (LLMs) in healthcare. We contribute to the literature with a focused assessment of LLMs for SHDG, including a review of early research in the area and recommendations for future research directions. Six promising research directions are identified for further investigation of LLMs for SHDG: evaluation metrics, LLM adoption, data efficiency, generalization, health equity, and regulatory challenges.

Key words: large language models; generative artificial intelligence; synthetic data; health equity; responsible AI.

Introduction

The recent release of generative large language models (LLMs), such as OpenAI's GPT models¹ and Google's PaLM² has generated both robust enthusiasm as well as significant concern related to the use of generative artificial intelligence (AI) in healthcare.^{3–5} Numerous potential applications for healthcare have been documented, including processing of administrative data, such as discharge summary generation, interfacing as a chatbot with doctors for diagnosis or treatment determination, interfacing as a chatbot with patients for mental healthcare delivery, producing clinical

trial documentation, intelligent tagging of patient images (eg, radiology or pathology images), and creation of educational health material.^{6–14} General-purpose LLMs have been found to achieve high performance on clinical licensing exams and comprehensive medical Q&A benchmarks,^{15–17} and LLMs trained on medical data have successfully augmented clinician diagnostic performance.¹⁸

In this perspective, we focus on 1 particularly promising avenue for LLMs: the creation of synthetic health data. There is a significant need for augmented datasets, as health data are often limited in size, may be costly to collect, not

Received: January 31, 2024; Revised: June 27, 2024; Editorial Decision: October 7, 2024; Accepted: October 11, 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of the American Medical Informatics Association.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

representative of diverse populations, and privacy concerns limit its sharing.^{19,20} Machine learning models for prediction and classification often require large datasets, particularly for deep learning models common in health.²¹ Yet datasets can be insufficiently large due to the rapid evolution of diseases, such as COVID-19,²² rarity of disease,²³ or the myriad obstacles to sharing and acquiring existing health data, including ethical, legal, political, economic, cultural, and technical barriers.^{24,25} Synthetic data provide a unique opportunity for health dataset expansion or creation, by addressing privacy concerns and other barriers. We build on existing research on the state of the art in synthetic health data generation (SHDG)^{20,23,26–32} and broad exploration of the potential risks and opportunities for LLMs in healthcare.⁶ We contribute to the literature with a focused assessment of LLMs for SHDG, including a review of early research in the area and recommendations for future research directions (see Figure 1 for a summary of the paper's key concepts).

Synthetic health data generation

Synthetic data can be characterized by a combination of their resemblance to and distance from real data—they aim to mimic the statistical distribution and usability of real data while restricting reidentification of original data points (ie, individuals). Common characteristics for assessing synthetic datasets include *data realism*, the extent to which the synthetic datasets resemble and reflect patterns in real datasets, *utility*, measured by the performance on predictive tasks, and *privacy*, evaluated by the risk of identification of patients or attributes in the original data.²⁰

Non-LLM approaches and unresolved challenges

Standard synthetic data generation methods seek to simulate the generating process of the original data through an estimation of the original data distributions. Classical statistical

approaches include kernel density estimation³³ and Markov Chain Monte Carlo.³⁴ However, these methods often impose limiting assumptions on the data distribution, which precludes estimation of the complex correlation structure typically found in medical data.²⁰ Popular state-of-the-art methods include Generative Adversarial Networks (GANs)³⁵ and variational autoencoders.³⁶ GANs are composed of 2 neural networks, a “generator” and a “discriminator,” trained in tandem. The generator’s objective is to create synthetic data indistinguishable from the real data, and the discriminator’s objective is to differentiate between the generated and real data. Variational autoencoders are also composed of 2 neural network models: the “encoder” aims to compress an original dataset into a latent representation and the “decoder” aims to decompress the latent representation back to the original data. The decoder can then be used to generate synthetic data. These methods have been used to generate a variety of health data types, including both snapshot and longitudinal electronic health record (EHR) data, sociodemographic data, lab/measurement data, and image data.^{30,37–41} We provide illustrative applications of these methods with recent examples from the literature.

Li et al⁴² developed a GAN-based model to simultaneously generate multiple types of clinical time series data. After training on 141 488 unique patients’ intensive care unit (ICU) data, they were able to synthesize sequences of patients’ health indicators, including oxygen level, blood pressure, and heart rate. They demonstrate that augmenting their real training data with synthetic data to increase training data size improves performance on a downstream task of predicting patients’ need for mechanical ventilation or vasopressors. However, this is achieved through significant data pre-processing, including imputation, smoothing, and truncation of time series. Biswal et al⁴³ proposed a variational autoencoder model to generate patients’ clinical encounters




Figure 1. An overview of the concepts and research directions discussed in the article.

and their corresponding features, including diagnoses, medications, and procedures. The authors were able to generate longitudinal encounter sequences for a chosen disease. The paper highlighted that complex longitudinal clinical interactions can be generated, but with the limitation of not being able to account for comorbidities from more than 1 disease. Collectively, the literature suggests that previous approaches can generate a wide variety of health data types, can focus on generation for specific health conditions, and incorporate privacy into model training.⁴⁴ A variety of other models have also been developed to handle varying time periods between clinical visits,⁴⁵ missing or incomplete original data,⁴⁶ and incorporation of disease-specific domain knowledge.⁴⁷ However, these models each have their drawbacks, such as their limited focus on 1 data modality or on 1 disease, or their inflexible data pre-processing requirements.

However, many technical challenges remain. Hernandez et al²⁶ and Ghosheh et al³¹ observe that current GAN-based approaches are tailored to specific data structures and contexts, making generalization and transfer between contexts difficult. Ghosheh et al³¹ also point out GAN's lack of ability to generate complex multimodal data, which has been shown to improve predictive performance.⁴⁸ Augmentation of real data with synthetic data has the potential to improve multimodality models' performance, yet current methods cannot generate data across data types. Murtaza et al²⁰ similarly point out that while existing methods have shown proficiency at synthesizing disease-specific longitudinal EHR data, "generating comprehensive longitudinal records with comorbidities remains an open challenge." Another issue is the difficulty of incorporating expert knowledge into generation methods, whether in the form of disease progression models or constraints on clinical knowledge violation.²⁰ Yan et al⁴⁹ found in their benchmarking study that all tested models made mistakes in assigning gender-specific disease codes to varying degrees. LLMs have the potential to overcome these current limitations.

Application of LLMs for SHDG

Although several studies have explored the use of LLMs for SHDG, both in the context of text-based tasks, such as generation or augmentation of clinical language,^{50,51} and tabular EHR data tasks,^{52–54} developments in this area are still nascent, focusing largely on proof-of-concept rather than field applications. Table 1 summarizes key recent studies investigating SHDG with LLMs. One of these studies, Yuan et al,⁵⁰ addressed the issue of matching patients, based on their EHR data, to clinical trials, accounting for the trials' inclusion and

exclusion criteria. Existing models generally have had limited success due to terminology discordance across the datasets, which renders matching more challenging. Thus, Yuan et al⁵⁰ used ChatGPT to augment inclusion and exclusion criteria descriptions for clinical trials in order to facilitate improved matching. Tang et al⁵¹ focused on the challenge of acquiring labeled data for 2 text classification tasks: recognition of biomedical vocabulary, or "entities," and extraction of relationships between those entities. They used ChatGPT to generate a synthetic dataset for these 2 tasks, incorporating a combination of prompt engineering (prompt engineering is the process of optimizing prompts given to interactive LLMs, such as ChatGPT, to achieve a certain task without having to further train the LLM) and human-labeled seed examples into their workflow. Borisov et al⁵² investigated the ability of LLMs to generate tabular data. They converted rows of heterogeneous features (both categorical and numerical) into sentence-like textual representation, fine-tuned (fine-tuning refers to a strategy of adapting pre-trained models to specific tasks, by using a dataset of labeled examples to update either the whole model, or by adding and training a relatively small number of additional layers) GPT-2 to generate similar synthetic text data, and then converted the synthesized text back into tabular data. Borisov et al,⁵² however, considered just 1 tabular health dataset, and did not evaluate privacy preservation characteristics. Seedat et al⁵³ examined the capabilities of GPT4 to generate tabular data out-of-the-box, using a 3-section prompt with data context, data examples, and generation instructions and post-generation filtering for data quality. They found that GPT4 generates high-utility data from few examples, holding promise for health applications with low data availability (eg, rare diseases). Finally, Kim et al⁵⁴ focus on synthetic data generation with LLMs in settings of outcome class imbalance, common in health settings. Using out-of-the-box generation with GPT4, Llama 2⁵⁸ and Mistral,⁵⁹ they find that prompts specifically identifying and partitioning examples from each class produce synthetic data that boost model performance for a minority class. Collectively, these studies highlight the potential of LLMs for multimodal synthetic data generation and generation from few training examples.

Open research directions

Given the limited research to date on LLMs for SHDG, many important questions remain around the potential opportunities and risks. Building on and extending systematic reviews of synthetic data generation in healthcare^{20,23,32–36} and

Table 1. Summary of current research applying LLMs to synthetic data generation.

Modality	Downstream application	LLM(s) used	Reference(s)
Text	Clinical trial-patient matching	GPT3	Yuan et al ⁵⁰
	Biomedical term comprehension	GPT3	Tang et al ⁵¹
	Radiology report generation	GPT4	Xie et al ⁵⁵
	Alzheimer's detection from EHR notes	GPT4	Li et al ⁵⁶
	Clinical NLP tasks (general purpose)	GPT3.5	Xu et al ⁵⁷
Tabular	Binary classification (general purpose)	GPT2	Borisov et al ⁵²
		GPT3.5, GPT4	^a Seedat et al ⁵³
		GPT3.5, LLaMa-2-7b, Mistral-7b	^a Kim et al ⁵⁴

^a Not currently peer reviewed.
Abbreviation: LLM, large language model.

benchmarking studies,^{49,60–63} we describe useful avenues for further research below.

Evaluation metrics

To fully understand the value potential of LLMs, it is important to establish a portfolio of metrics to evaluate the quality of the generated data and to compare synthetic data generating LLMs to the current state of the art. There is already a lack of standardization of metrics in the broader field of health data generation^{20,26,28} and metrics for LLM performance on clinical prediction tasks.⁶⁴ Dimensions that are critical to measure include the aforementioned data realism, utility, and privacy, token usage, computational cost (including power consumption), and diversity. Researchers should aim to present results on benchmark datasets and metrics, as well as assessments specific to a potential deployment context.

Some evaluation criteria have established metrics, such as the predictive performance of a downstream machine learning (ML) model after augmentation with synthetic data, which is both common²⁸ and considers a likely setting for EHR data use. Computational cost metrics have recently become more prevalent²⁶ and are particularly important in the LLM context, given the high costs of training and prompting, whether monetary or environmental.⁶⁵ Efficiency metrics, such as generation time, algorithmic complexity, and computing power required, can help organizations make economic assessments of synthetic data generation alternatives. When evaluating privacy, metrics should focus on risks specific to healthcare data, such as re-identification, using measurements like the ability to predict whether a real data point belonged to the generator's training set.²⁸ One must also consider unique vulnerabilities of the LLMs. For example, ChatGPT is vulnerable to prompt injection, where users design prompts to reveal sensitive data that ChatGPT is intended not to expose.⁶⁶ Thus, a new privacy metric could evaluate whether the generating LLMs reveal private medical information across a range of prompts. Furthermore, given the breadth of LLM training data, new categories of risks must be anticipated, including inadvertent infringement of intellectual property or generation of toxic or harmful language.⁶⁷

Given existing research questioning the value of general-purpose models over tailored clinical models,⁶⁸ a comprehensive comparison of LLM-based methods to tailored methods for synthetic data generation across a portfolio of relevant metrics is critical.

LLM adoption

Choices related to the specific LLM model to be deployed as well as the generation approach are critical to understand. In the context of synthetic data, both prompt engineering and fine-tuning have already been applied.^{51,52} Prompt engineering can involve a variety of prompt templates and include either few or zero examples as part of the prompt⁶⁹—an example of a zero-example prompt is shown in Figure 2. Similarly, one can explore or develop multiple different fine-tuning approaches.⁷⁰ Furthermore, there are many existing LLMs, each of which may be more appropriate for certain approaches—fine-tuning may be easier with “smaller” LLMs such as Llama⁷¹ whereas prompt engineering is better suited for “larger” LLMs such as GPT-4. These choices can also be framed in the tradeoff between “buy” versus “build”—do the

benefits of fine-tuning LLM models over direct application of out-of-the-box models outweigh the fine-tuning development cost? Extensive exploration of such strategic choices in adoption is necessary to make informed decisions for a specific context and task.

Data efficiency

While the promise of synthetic data is clear, the practical feasibility of creating quality data must address the question of how much real data are necessary to generate high-fidelity synthetic observations. Given the large number of rare diseases and conditions (McDuff et al., 2023),²³ well-documented difficulties of acquiring health data, the privacy risks involved with sharing increasing patient data with models, and the potential costs of fine-tuning LLMs with increasing data,⁷² there is great interest in maximizing the data efficiency of synthetic data generating LLMs. However, providing fewer examples can lead to decreased generating ability,⁴² particularly of rare real cases that are all the more important to have represented in synthetic data. Yet, LLMs have a crucial advantage in this environment. As shown by Seedat et al,⁵³ LLMs can leverage prior knowledge from training to generate synthetic tabular data from very few examples. Application of their and related methods to health data holds great promise for the many low data contexts in healthcare, that should be explored.

Generalization

As previously noted, non-LLM-based models for synthetic data generation struggle to generalize, whether in handling multiple data modalities, transferring between health contexts, or incorporating domain knowledge.^{26,31} Because LLMs are general purpose models trained on diverse knowledge bases, they are well-equipped to handle each of these challenges. Borisov et al⁵² showed that LLMs can simultaneously generate different data modalities with little tailoring, whether discrete, continuous, or categorical text data. Gruver et al⁷³ demonstrated that LLMs can generate time series forecasts, while also handling missing data and creating textual explanations of predictions. Additionally, there are many existing LLMs trained specifically on medical text corpuses such as ClinicalBERT, Med-PaLM, and GatorTron which have the potential to automatically incorporate their domain knowledge into data generation.^{74–76} Thus, an important question for future work is a deeper understanding of if and how LLMs can convert knowledge from their training data into generalization across data modalities and contexts.

Health equity

Another critical area that warrants further research is the risks and opportunities of synthetic data generation with LLMs in the domain of health equity. One clear risk is the perpetuation of existing biases in the data used to train LLMs and biases in health data^{77,78}—Bhanot et al⁷⁹ have documented violations of fairness metrics in existing synthetic data generation methods. For instance, they found that the realism of synthetic sleep data was not equal across age groups.

However, as noted by McDuff et al,²³ synthetic data generation also provides opportunities to correct existing health equity issues. For instance, machine learning models often underperform for minority groups due to a lack of training data.⁸⁰ Racial minorities are underrepresented in clinical

<p>Prompt: I'd like to generate synthetic health data for breast cancer patients. Can you provide a fictional series of health provider encounters, including dates, diagnoses, procedures, and lab/test results for a single breast cancer patient?</p>	<p>LLM: Yes, I can generate synthetic breast cancer encounter data. Here is a series for one patient: This patient received a mammogram on March 3rd, 2019. After receiving an abnormal finding, the patient returned for a core biopsy on March 10th, 2019, which returned as "Ductal Carcinoma In Situ". On April 14th, 2019, the patient received a mastectomy. After finding positive margins, the patient received radiation therapy, which included 3 visits on May 1st, May 8th, and May 15th.</p>																														
<p>Prompt: Thank you. Can you convert this into two tables – one with diagnoses and procedures, and the other with lab/test results. Please include ICD10 for diagnoses and CPT codes for procedures.</p>	<div><div><p>LLM:</p><table><tr><th colspan="3">Procedures</th></tr><tr><th>Date</th><th>Diag.</th><th>Proc.</th></tr><tr><td>3/3/19</td><td>C50</td><td>77046</td></tr><tr><td>3/10/19</td><td>C50</td><td>19083</td></tr><tr><td></td><td>⋮</td><td></td></tr></table></div><div><table><tr><th colspan="3">Labs/Tests</th></tr><tr><th>Date</th><th>Test</th><th>Result</th></tr><tr><td>3/3/19</td><td>77046</td><td>Abnormal</td></tr><tr><td>3/10/19</td><td>19083</td><td>DCIS</td></tr><tr><td></td><td>⋮</td><td></td></tr></table></div></div>	Procedures			Date	Diag.	Proc.	3/3/19	C50	77046	3/10/19	C50	19083		⋮		Labs/Tests			Date	Test	Result	3/3/19	77046	Abnormal	3/10/19	19083	DCIS		⋮	
Procedures																															
Date	Diag.	Proc.																													
3/3/19	C50	77046																													
3/10/19	C50	19083																													
	⋮																														
Labs/Tests																															
Date	Test	Result																													
3/3/19	77046	Abnormal																													
3/10/19	19083	DCIS																													
	⋮																														

Figure 2. An example of synthetic health data generation with prompts to a large language model (LLM).

trials and in health data⁸¹—synthetic data generation can help increase representation of smaller groups in augmented datasets and boost performance of these models for underrepresented groups. Thus, 1 valuable research direction is to compare the boost in performance for minority groups that LLM-based synthetic data provide over other common ML fairness methods aimed at improving performance for small groups.

Regulatory challenges

Moving forward, the regulatory environment for generative AI will likely evolve rapidly. Regulation of LLMs in general, and synthetic health data in particular, is not clearly delineated in current data protection guidelines (eg, The General Data Protection Regulation [GDPR]).⁸² However, privacy preservation is a key policy requirement in emerging legislation on AI such as the EU AI Act⁸³ and the Executive Order issued in the United States.⁸⁴ Giuffrè et al⁸⁵ discuss the difficulty of proving whether synthetic data are fully anonymized, as required by GDPR, as recent methods claiming to achieve de-identification were shown to retain vulnerability to re-identification attacks. One must also consider the privacy policies of LLM providers. For example, OpenAI's policies around storing user data, training future models on user data, and sharing data with third parties may preclude researchers from providing sensitive patient data in input prompts.⁸⁶ There are also considerations for the data used to validate the performance and safety of medical devices, which regulators must consider; relatedly, the Food and Drug Administration (FDA) and the Advanced Research Projects Agency for Health (ARPA-H) recently launched a program to help facilitate access to broader diversity in training and test data to better empower FDA pre-market submissions.⁸⁷ The intersection between the regulatory landscape and the use of LLMs for SHDG represents a final opportunity for further work.

Conclusion

LLMs have already shown great promise in a variety of healthcare applications, and SHDG is a logical next high-impact application area of LLMs. These methods can provide

opportunities to address persistent challenges such as fairness in health modeling. However, we must ensure that potential drawbacks to LLM-based models are carefully examined as well. Each of these concerns—privacy, data efficiency, or bias perpetuation—is an important area of research as we develop new LLM-based synthetic health generation approaches.

Author contributions

Concept and design (Ritu Agarwal, Margrét V. Bjarnadóttir, and Kenyon Crowley), drafting of manuscript (Daniel Smolyak, Ritu Agarwal, and Margrét V. Bjarnadóttir), critical revision of manuscript for important intellectual content (Daniel Smolyak, Ritu Agarwal, Margrét V. Bjarnadóttir, and Kenyon Crowley), statistical analysis (N/A), and obtained funding (N/A).

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors have no competing interests to declare.

Data availability

There are no new data associated with this article.

References

- GPT-4. Accessed October 9, 2023. <https://openai.com/gpt-4>
- Google AI PaLM 2. Google AI. Accessed October 9, 2023. <https://ai.google/discover/palm2/>
- The Lancet Digital Health. ChatGPT: friend or foe? *Lancet Digit Health*. 2023;5:e102. [https://doi.org/10.1016/S2589-7500\(23\)00023-7](https://doi.org/10.1016/S2589-7500(23)00023-7)
- Asch DA. An interview with ChatGPT about health care. *Catalyst*. 2023;4.
- Lee P, Bubeck S, Petro J. Benefits, limits, and risks of GPT-4 as an AI chatbot for medicine. *N Engl J Med*. 2023;388:1233-1239. <https://doi.org/10.1056/NEJMSr2214184>

6. Thirunavukarasu AJ, Ting DSJ, Elangovan K, et al. Large language models in medicine. *Nat Med*. 2023;29:1930-1940. <https://doi.org/10.1038/s41591-023-02448-8>
7. Cascella M, Montomoli J, Bellini V, et al. Evaluating the feasibility of ChatGPT in healthcare: an analysis of multiple clinical and research scenarios. *J Med Syst*. 2023;47:33. <https://doi.org/10.1007/s10916-023-01925-4>
8. Lai T, Shi Y, Du Z, et al. Psy-LLM: scaling up global mental health psychological services with AI-based large language models. 2023. Accessed October 6, 2023. <http://arxiv.org/abs/2307.11991>
9. Lim S, Schmälzle R. Artificial intelligence for health message generation: an empirical study using a large language model (LLM) and prompt engineering. *Front Commun*. 2023;8:1129082.
10. Sallam M. ChatGPT utility in healthcare education, research, and practice: systematic review on the promising perspectives and valid concerns. *Healthcare (Basel)*. 2023;11:887. <https://doi.org/10.3390/healthcare11060887>
11. Liu J, Wang C, Liu S. Utility of ChatGPT in clinical practice. *J Med Internet Res*. 2023;25:e48568. <https://doi.org/10.2196/48568>
12. Javaid M, Haleem A, Singh RP. ChatGPT for healthcare services: an emerging stage for an innovative perspective. *TBench*. 2023;3:100105. <https://doi.org/10.1016/j.tbench.2023.100105>
13. Morley J, DeVito NJ, Zhang J. Generative AI for medical research. *BMJ*. 2023;382:1551. <https://doi.org/10.1136/bmj.p1551>
14. Liu S, Wright AP, Patterson BL, et al. Using AI-generated suggestions from ChatGPT to optimize clinical decision support. *J Am Med Inform Assoc*. 2023;30:1237-1245. <https://doi.org/10.1093/jamia/ocad072>
15. Strong E, DiGiammarino A, Weng Y, et al. Chatbot vs medical student performance on free-response clinical reasoning examinations. *JAMA Intern Med*. 2023;183:1028-1030. <https://doi.org/10.1001/jamainternmed.2023.2909>
16. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. *Nature*. 2023;620:172-180. <https://doi.org/10.1038/s41586-023-06291-2>
17. Liévin V, Hother CE, Winther O. Can large language models reason about medical questions? 2023. Accessed October 6, 2023. <http://arxiv.org/abs/2207.08143>
18. McDuff D, Schaekermann M, Tu T, et al. Towards accurate differential diagnosis with large language models. 2023. Accessed January 13, 2024. <http://arxiv.org/abs/2312.00164>
19. Chen RJ, Lu MY, Chen TY, et al. Synthetic data in machine learning for medicine and healthcare. *Nat Biomed Eng*. 2021;5:493-497. <https://doi.org/10.1038/s41551-021-00751-8>
20. Murtaza H, Ahmed M, Khan NF, et al. Synthetic data generation: state of the art in health care domain. *Comput Sci Rev*. 2023;48:100546. <https://doi.org/10.1016/j.cosrev.2023.100546>
21. Abdel-Jaber H, Devassy D, Al Salam A, et al. A review of deep learning algorithms and their applications in healthcare. *Algorithms*. 2022;15:71. <https://doi.org/10.3390/a15020071>
22. Waheed A, Goyal M, Gupta D, et al. CovidGAN: data augmentation using auxiliary classifier GAN for improved COVID-19 detection. *IEEE Access*. 2020;8:91916-91923. <https://doi.org/10.1109/ACCESS.2020.2994762>
23. McDuff D, Curran T, Kadambi A. Synthetic data in healthcare. 2023. Accessed September 26, 2023. <http://arxiv.org/abs/2304.03243>
24. van Panhuis WG, Paul P, Emerson C, et al. A systematic review of barriers to data sharing in public health. *BMC Public Health*. 2014;14:1144. <https://doi.org/10.1186/1471-2458-14-1144>
25. Rhodes KL, Echo-Hawk A, Lewis JP, et al. Centering data sovereignty, tribal values, and practices for equity in American Indian and Alaska native public health systems. *Public Health Rep*. 2024;139:105-155. <https://doi.org/10.1177/00333549231199477>
26. Hernandez M, Epelde G, Alberdi A, et al. Synthetic data generation for tabular health records: a systematic review. *Neurocomputing*. 2022;493:28-45. <https://doi.org/10.1016/j.neucom.2022.04.053>
27. Gonzales A, Guruswamy G, Smith SR. Synthetic data in health care: a narrative review. *PLOS Digit Health*. 2023;2:e0000082. <https://doi.org/10.1371/journal.pdig.0000082>
28. Kaabachi B, Despraz J, Meurers T, et al. Can we trust synthetic data in medicine? A scoping review of privacy and utility metrics. 2023. Accessed January 8, 2024. <https://www.medrxiv.org/content/10.1101/2023.11.28.23299124v1>
29. Tsao S-F, Sharma K, Noor H, et al. Health synthetic data to enable health learning system and innovation: a scoping review. *Stud Health Technol Inform*. 2023;302:53-57. <https://doi.org/10.3233/SHTI230063>
30. Georges-Filteau J, Cirillo E. Synthetic observational health data with GANs: from slow adoption to a boom in medical research and ultimately digital twins? 2020. Accessed October 6, 2023. <http://arxiv.org/abs/2005.13510>
31. Ghosheh GO, Li J, Zhu T. A survey of generative adversarial networks for synthesizing structured electronic health records. *ACM Comput Surv*. 2024;56:1-34. <https://doi.org/10.1145/3636424>
32. Perkonoja K, Auranen K, Virta J. Methods for generating and evaluating synthetic longitudinal patient data: a systematic review. 2023. Accessed January 13, 2024. <http://arxiv.org/abs/2309.12380>
33. Foraker RE, Yu SC, Gupta A, et al. Spot the difference: comparing results of analyses from real patient data and synthetic derivatives. *JAMIA Open*. 2020;3:557-566. <https://doi.org/10.1093/jamiaopen/ooaa060>
34. Park Y, Ghosh J, Shankar M. Perturbed Gibbs Samplers for generating large-scale privacy-safe synthetic health data. In: *2013 IEEE International Conference on Healthcare Informatics*, Philadelphia, PA, USA. 2013:493-498.
35. Goodfellow I, Pouget-Abadie J, Mirza M, et al. Generative adversarial nets. *Adv Neural Inf Process Syst*. 2014;27.
36. Kingma DP, Welling M. Auto-encoding variational Bayes. 2022. Accessed November 2, 2023. <http://arxiv.org/abs/1312.6114>
37. Choi E, Biswal S, Malin B, et al. Generating multi-label discrete patient records using generative adversarial networks. In: *Proceedings of the 2nd Machine Learning for Healthcare Conference*, Boston, MA, USA. PMLR; 2017:286-305.
38. Bilici Ozyigit E, Arvanitis TN, Despotou G. Generation of realistic synthetic validation healthcare datasets using generative adversarial networks. *Stud Health Technol Inform*. 2020;272:322-325. <https://doi.org/10.3233/SHTI200560>
39. Kaur D, Sobieski M, Patil S, et al. Application of Bayesian networks to generate synthetic health data. *J Am Med Inform Assoc*. 2021;28:801-811. <https://doi.org/10.1093/jamia/ocaa303>
40. Koivu A, Sairanen M, Airola A, et al. Synthetic minority oversampling of vital statistics data with generative adversarial networks. *J Am Med Inform Assoc*. 2020;27:1667-1674. <https://doi.org/10.1093/jamia/ocaa127>
41. Zhang Z, Yan C, Malin BA. Keeping synthetic patients on track: feedback mechanisms to mitigate performance drift in longitudinal health data simulation. *J Am Med Inform Assoc*. 2022;29:1890-1898. <https://doi.org/10.1093/jamia/ocac131>
42. Li J, Cairns BJ, Li J, et al. Generating synthetic mixed-type longitudinal electronic health records for artificial intelligent applications. *NPJ Digit Med*. 2023;6:98. <https://doi.org/10.1038/s41746-023-00834-7>
43. Biswal S, Ghosh S, Duke J, et al. EVA: generating longitudinal electronic health records using conditional variational autoencoders. In: *Proceedings of the 6th Machine Learning for Healthcare Conference*. PMLR; 2021:260-282.
44. Torfi A, Fox EA, Reddy CK. Differentially private synthetic medical data generation using convolutional GANs. *Inf Sci*. 2022;586:485-500. <https://doi.org/10.1016/j.ins.2021.12.018>
45. Wang X, Lin Y, Xiong Y, et al. Using an optimized generative model to infer the progression of complications in type 2 diabetes patients. *BMC Med Inform Decis Mak*. 2022;22:174. <https://doi.org/10.1186/s12911-022-01915-5>

46. Yu M, He Y, Raghunathan TE. A semiparametric multiple imputation approach to fully synthetic data for complex surveys. *J Surv Stat Methodol*. 2022;10:618-641. <https://doi.org/10.1093/jssam/sm1016>
47. Sood M, Sahay A, Karki R, et al. Realistic simulation of virtual multi-scale, multi-modal patient trajectories using Bayesian networks and sparse auto-encoders. *Sci Rep*. 2020;10:10971. <https://doi.org/10.1038/s41598-020-67398-4>
48. Soenksen LR, Ma Y, Zeng C, et al. Integrated multimodal artificial intelligence framework for healthcare applications. *NPJ Digit Med*. 2022;5:149. <https://doi.org/10.1038/s41746-022-00689-4>
49. Yan C, Yan Y, Wan Z, et al. A multifaceted benchmarking of synthetic electronic health record generation models. *Nat Commun*. 2022;13:7609. <https://doi.org/10.1038/s41467-022-35295-1>
50. Yuan J, Tang R, Jiang X, et al. Large language models for healthcare data augmentation: an example on patient-trial matching. 2023. Accessed September 26, 2023. <http://arxiv.org/abs/2303.16756>
51. Tang R, Han X, Jiang X, et al. Does synthetic data generation of LLMs help clinical text mining? 2023. Accessed September 26, 2023. <http://arxiv.org/abs/2303.04360>
52. Borisov V, Sessler K, Leemann T, et al. Language models are realistic tabular data generators. 2022. Accessed September 26, 2023. <https://arxiv.org/abs/2210.06280>
53. Seedat N, Huynh N, van Breugel B, et al. Curated LLM: synergy of LLMs and data curation for tabular augmentation in ultra low-data regimes. 2023. Accessed January 13, 2024. <http://arxiv.org/abs/2312.12112>
54. Kim J, Kim T, Choo J. Exploring prompting methods for mitigating class imbalance through synthetic data generation with large language models. 2024. Accessed June 25, 2024. <http://arxiv.org/abs/2404.12404>
55. Xie Y, Chen Q, Wang S, et al. PairAug: what can augmented image-text pairs do for radiology? Accessed June 24, 2024. <https://arxiv.org/abs/2404.04960v1>
56. Li R, Wang X, Yu H. Two directions for clinical data generation with large language models: data-to-label and label-to-data. *Proc Conf Empir Methods Nat Lang Process*. 2023;2023:7129-7143. <https://doi.org/10.18653/v1/2023.findings-emnlp.474>
57. Xu R, Cui H, Yu Y, et al. Knowledge-infused prompting improves clinical text generation with large language models. In: *NeurIPS 2023 Workshop on Synthetic Data Generation with Generative AI*, New Orleans, LA, USA. 2023.
58. Touvron H, Martin L, Stone K, et al. Llama 2: open foundation and fine-tuned chat models. 2023. Accessed June 17, 2024. <http://arxiv.org/abs/2307.09288>
59. Jiang AQ, Sablayrolles A, Mensch A, et al. Mistral 7B. 2023. Accessed June 17, 2024. <http://arxiv.org/abs/2310.06825>
60. El Emam K, Mosquera L, Fang X, et al. Utility metrics for evaluating synthetic health data generation methods: validation study. *JMIR Med Inform*. 2022;10:e35734. <https://doi.org/10.2196/35734>
61. El Kababji S, Mitsakakis N, Fang X, et al. Evaluating the utility and privacy of synthetic breast cancer clinical trial data sets. *JCO Clin Cancer Inform*. 2023;7:e2300116. <https://doi.org/10.1200/CCI.23.00116>
62. Benaim AR, Almog R, Gorelik Y, et al. Analyzing medical research results based on synthetic data and their relation to real data results: systematic comparison from five observational studies. *JMIR Med Inform*. 2020;8:e16492. <https://doi.org/10.2196/16492>
63. Hernandez M, Epelde G, Alberdi A, et al. Synthetic tabular data evaluation in the health domain covering resemblance, utility, and privacy dimensions. *Methods Inf Med*. 2023;62:e19-e38. <https://doi.org/10.1055/s-0042-1760247>
64. Wornow M, Xu Y, Thapa R, et al. The shaky foundations of large language models and foundation models for electronic health records. *NPJ Digit Med*. 2023;6:135. <https://doi.org/10.1038/s41746-023-00879-8>
65. Strubell E, Ganesh A, McCallum A. Energy and policy considerations for deep learning in NLP. In: Korhonen A, Traum D, Màrquez L, eds. *Proceedings of the 57th Annual Meeting of the Association for Computational Linguistics*, Florence, Italy. Association for Computational Linguistics; 2019:3645-3650.
66. Gupta M, Akiri C, Aryal K, et al. From ChatGPT to ThreatGPT: impact of generative AI in cybersecurity and privacy. *IEEE Access*. 2023;11:80218-80245. <https://doi.org/10.1109/ACCESS.2023.3300381>
67. Solaiman I, Talat Z, Agnew W, et al. Evaluating the social impact of generative AI systems in systems and society. 2023. Accessed October 6, 2023. <http://arxiv.org/abs/2306.05949>
68. Lehman E, Hernandez E, Mahajan D, et al. Do we still need clinical language models? 2023. Accessed October 8, 2023. <http://arxiv.org/abs/2302.08091>
69. Wang J, Shi E, Yu S, et al. Prompt engineering for healthcare: methodologies and applications. 2023. Accessed October 12, 2023. <http://arxiv.org/abs/2304.14670>
70. Sun C, Qiu X, Xu Y, et al. How to fine-tune BERT for text classification? In: Sun M, Huang X, Ji H, et al., eds. *Chinese Computational Linguistics*. Springer International Publishing; 2019:194-206.
71. Gema AP, Daines L, Minervini P, et al. Parameter-efficient fine-tuning of LLaMA for the clinical domain. 2023. Accessed October 17, 2023. <http://arxiv.org/abs/2307.03042>
72. Zhao WX, Zhou K, Li J, et al. A survey of large language models. 2023. Accessed October 9, 2023. <http://arxiv.org/abs/2303.18223>
73. Gruver N, Finzi M, Qiu S, et al. Large language models are zero-shot time series forecasters. 2023. Accessed January 14, 2024. <http://arxiv.org/abs/2310.07820>
74. Huang K, Altosaar J, Ranganath R. ClinicalBERT: modeling clinical notes and predicting hospital readmission. 2020. Accessed January 14, 2024. <http://arxiv.org/abs/1904.05342>
75. Singhal K, Tu T, Gottweis J, et al. Towards expert-level medical question answering with large language models. 2023. Accessed January 14, 2024. <http://arxiv.org/abs/2305.09617>
76. Yang X, Chen A, PourNejatian N, et al. GatorTron: a large clinical language model to unlock patient information from unstructured electronic health records. 2022. Accessed January 14, 2024. <http://arxiv.org/abs/2203.03540>
77. Bender EM, Gebru T, McMillan-Major A, et al. On the dangers of stochastic parrots: can language models be too big? In: *Proceedings of the 2021 ACM Conference on Fairness, Accountability, and Transparency*. ACM; 2021:610-623.
78. Chen IY, Pierson E, Rose S, et al. Ethical machine learning in healthcare. *Annu Rev Biomed Data Sci*. 2021;4:123-144. <https://doi.org/10.1146/annurev-biodatasci-092820-114757>
79. Bhanot K, Qi M, Erickson JS, et al. The problem of fairness in synthetic healthcare data. *Entropy (Basel)*. 2021;23:1165. <https://doi.org/10.3390/e23091165>
80. Buolamwini J, Gebru T. Gender shades: intersectional accuracy disparities in commercial gender classification. In: *Proceedings of the 1st Conference on Fairness, Accountability and Transparency*, New York City, NY, USA. PMLR; 2018:77-91.
81. Nazha B, Mishra M, Pentz R, et al. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. *Am Soc Clin Oncol Educ Book*. 2019;39:3-10. https://doi.org/10.1200/EDBK_100021
82. Meskó B, Topol EJ. The imperative for regulatory oversight of large language models (or generative AI) in healthcare. *NPJ Digit Med*. 2023;6:120-126. <https://doi.org/10.1038/s41746-023-00873-0>
83. The Act Texts | EU Artificial Intelligence Act. Accessed June 18, 2024. <https://artificialintelligenceact.eu/the-act/>
84. The White House. Executive order on the safe, secure, and trustworthy development and use of artificial intelligence. The White

- House; 2023. Accessed June 18, 2024. <https://www.whitehouse.gov/briefing-room/presidential-actions/2023/10/30/executive-order-on-the-safe-secure-and-trustworthy-development-and-use-of-artificial-intelligence/>
85. Giuffrè M, Shung DL. Harnessing the power of synthetic data in healthcare: innovation, application, and privacy. *NPJ Digit Med.* 2023;6:186-188. <https://doi.org/10.1038/s41746-023-00927-3>
86. Wu X, Duan R, Ni J. Unveiling security, privacy, and ethical concerns of ChatGPT. *J Inf Intell.* 2024;2:102-115. <https://doi.org/10.1016/j.jiixd.2023.10.007>
87. ARPA-H Announces Medical Imaging Data Partnership with FDA | ARPA-H. 2024. Accessed June 24, 2024. <https://arpa-h.gov/news-and-events/arpa-h-announces-medical-imaging-data-partnership-fda>